AMGN compared with REPL: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

REPLReplimune Group, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

REPLReplimune Group, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

REPL: latest quarter not drawable.Method ›

Price

rebased to 0%

AMGN, solidREPL, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No shared counterparties.

Only REPL 6

AMGNAmgensupplier

BMYBristol Myers Squibbsupplier

REGNRegeneronsupplier

—Rocheunlisted

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

supplier

2 more · REPL chain ›

AMGNAmgen Inc

478.34· pre 483.00· delayed

Mkt cap$258.8BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

REPLReplimune Group, Inc.

20.67· pre 20.67· delayed

Pre-marketNov 5 '26delayed

Mkt cap$2.0BRevenue—Revenue—

Compare

Pre-marketNov 5 '26delayed

AMGNAmgen Inc

REPLReplimune Group, Inc.

478.34pre 483.00delayed

Price

20.67pre 20.67delayed

$258.8B

Mkt cap

$2.0B

Q3 FY26$10.4B

Revenue

—

FY25$36.8B

Revenue

—

AMGN478.34vsREPL20.67Pre-marketNov 5 '26delayed